Clinical Trial Update: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

Phase III trial of Tariquidar with Paclitaxel/Carboplatin as first-line therapy in non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Tariquidar (tariquidar)

Snippet

Sponsor: QLT Inc. | Conditions: Stage IIIb Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | Phase 3 | Status: TERMINATED